|
Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients Clinical research trials and Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients. Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients clinical trial. Human subjects often obtain the finest healthcare possible for their Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients  Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients
Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients
For Condition: Diabetes Mellitus, Type 1,Diabetes Mellitus, Type 2
Status: Completed
Sponsor(s): GMP Endotherapeutics ,
Synopsis: The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of intramuscular INGAP Peptide given for the first time in humans as a potential treatment for diabetes.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/70 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: Patients meeting all of the following inclusion criteria at screening can be considered for admission to the study. Stage 1 and Stage 2: 1. Male and female patients with, type 1 diabetes mellitus that are 18 through 70 years of age, or type 2 diabetes mellitus that are 30 through 70 years of age. 2. Patients who are insulin deficient and are diagnosed with type 1 or type 2 diabetes mellitus, and are currently well managed with insulin, with or without metformin. 3. Patients who have been on stable doses of insulin treatment for 90 days prior to study randomization. Exclusion Criteria: Patients meeting any of the following exclusion criteria at screening will not be enrolled in the study: 1. Patients with a history of any clinically significant retinopathy, symptomatic autonomic neuropathy, unstable angina, or kidney problems. 2. Patients with an uncontrolled or untreated significant pulmonary, neurological condition, or cardiovascular disease, including hypertension, congestive heart failure, angina, or peripheral vascular disease. 3. Patients who have received any investigational product within 30 days of admission into the study. 4. Patients with a history or clinical evidence of multiple organ autoimmune disorders. 5. Patients with a medical condition, serious intercurrent illness, or extenuating circumstance that would significantly decrease study compliance, including all prescribed follow-up. 6. Patients who are lactating and breastfeeding.
Total Enrollment: 62
Location and Contact Information:
VASDHS Medical Center
San Diego, California, 92161
United States
UNC Diabetes, Endocrinology, Metabolism Clinic
Durham, North Carolina, 27713
United States
MedStar Research Institute - Clinical Research Center
Washington D.C., District of Columbia, 20003
United States
Texas Diabetes Institute
San Antonio, Texas, 78284
United States
Additional Information:
Study ID Numbers: INGAP-01-001;
Study Start Date: December 2001
Record last reviewed: June 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00034255
Other Diabetes Mellitus, Type 2 Studies:
1. Effect of AC2993 Compared with Insulin Glargine in Patients with Type 2 Diabetes Also Using Combination Therapy with Sulfonylurea and Metformin
2. Lifestyle interventions to reduce diabetes risk
3. Native Hawaiian Diabetes Intervention Program
4. Pilot Study of Vedic Medicine for Type 2 Diabetes
5. Evaluation of the Effect of Pramlintide on Satiety and Food Intake
Related Studies:
Other Diabetes Mellitus, Type 2 Clinical Trials
Other California Clinical Trials
Other San Diego Clinical Trials
Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients
|
|
|
|
|
|
|
|
